NMR Quantification of TMAO
AssigneeLipoScience, Inc.
InventorsJames D. Otvos, Elias J. Jeyarajah, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Dennis W. Bennett, Steven P. Matyus, Stanley L. Hazen
Life of this patent
Estimating the term…
Abstract
A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosample may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 μM or urine with a normal biologic range of between about 0-1000 μM.
Claims15
A method of determining a measure of TMAO in in vitro biosamples, comprising:
- generating a proton NMR spectrum for an in vitro biosample;
- and
- electronically determining a level of trimethylamine-N-oxide (“TMAO”) in the in vitro biosample using a defined TMAO peak region having a single TMAO peak residing between about 3.2 and 3.4 ppm of the proton NMR spectrum.
(canceled)
11-22. (canceled)
A processor configured to evaluate in vitro biosamples, the processor configured to
- generate a proton NMR spectrum for an in vitro biosample;
- and
- electronically determine NMR signal in at least one defined peak region that includes a trimethylamine-N-oxide (TMAO) peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample to determine a level of TMAO.
24-53. (canceled)
A method of monitoring patients for therapeutic treatment, comprising:
- electronically determining a level of trimethylamine-N-oxide (“TMAO”) in an in vitro biosample from the subject using a defined TMAO peak region having a single TMAO peak residing between about 3.2 and 3.4 ppm of a proton NMR spectrum;
- and
- administering a prebiotic, probiotic, or drug to the patient based on the level of TMAO in the biosample.
Dependencies are inferred from the claim text.